Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010

Vaccine

Volumn 30, Issue 35, 2012, Pages 5229-5234

  Chaibou, Maman S ^a   Bako, Harouna ^a   Salisou, Laouali ^a   Yaméogo, Téné M ^b   Sambo, Mariama ^c   Kim, Sung Hye ^d   Djingarey, Mamoudou H ^e   Zuber, Patrick L F ^e   Perea, William A ^e   Pezzoli, Lorenzo ^f  

^a National Hospital   (Niger)

^b Consultant for the Meningitis Vaccine Project ^*  (Burkina Faso)

^c Ministry of Public Health   (Niger)

^d International Vaccine Institute   (South Korea)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f NONE   (United Kingdom)

Author keywords

Adverse events following immunization (AEFI); Africa; MenAfriVac; Meningitis; Monitoring; Niger; Pharmacovigilance; Vaccine safety

Indexed keywords

MENINGITIS VACCINE;

ABSCESS; ARTHRALGIA; ARTICLE; ASTHENIA; BRONCHOSPASM; CONVULSION; CRYING; DIARRHEA; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECZEMA; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTHERMIA; IMMUNIZATION; INJECTION SITE PAIN; LYMPHADENOPATHY; MALAISE; MENINGITIS; MYALGIA; NEISSERIA MENINGITIDIS; NIGER; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SLEEP DISORDER; SYNCOPE; URTICARIA; VACCINATION; VERTIGO; VOMITING;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AFRICA SOUTH OF THE SAHARA; CHILD; CHILD, PRESCHOOL; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP A; NIGER; POPULATION SURVEILLANCE; VACCINATION; VACCINES, CONJUGATE;

EID: 84863834863     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.006     Document Type: Article

References (42)

1. Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999, 93(July (4)):341-353.
2. Chippaux J.P. Control of meningococcal meningitis outbreaks in sub-Saharan Africa. J Infect Dev Ctries 2008, 2(5):335-345.
3. World Health Organization Meningitis in Chad, Niger and Nigeria: 2009 epidemic season. Wkly Epidemiol Rec 2010, 85(19 February (8)):47-63.
4. LaForce F.M., Konde K., Viviani S., Preziosi M.P. The meningitis vaccine project. Vaccine 2007, 25(3 September (Suppl 1)):A97-A100.
5. Bishai D.M., Champion C., Steele M.E., Thompson L. Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa. Health Aff (Millwood) 2011, 30(June (6)):1058-1064.
6. LaForce F.M., Okwo-Bele J.M. Eliminating epidemic group a meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011, 30(June (6)):1049-1057.
7. World Health Organization Global Advisory Committee on vaccine safety, report of meeting held 16-17 June 2010. Wkly Epidemiol Rec 2010, 84(32):325-332.
8. Ouandaogo C.R., Yameogo T.M., Diomande F.V., Sawadogo C., Ouédraogo B., Ouédraogo-Traoré R., et al. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Vaccine 2012, 30(30 April (Suppl 2)):B46-B51.
9. Kim S.H., Pezzoli L., Yacouba H., Coulibaly T., Djingarey M.H., Perea W.A., et al. Whom and where are we not vaccinating? Coverage after the Introduction of a new conjugate vaccine against Group A meningococcus in Niger in 2010. PLoS One 2012, 7(1):e29116.
10. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364(16 June (24)):2293-2304.
11. Global Advisory Committee on Vaccine Safety, World Health Organization Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS. Expert Rev Vaccines 2009, 8(June (6)):705-716.
12. Edwards I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000, 356(7 October (9237)):1255-1259.
13. Kohl KS, Bonhoeffer J, Braun MM, Chen RT, Duclos P, Heijbel H, et al. The Brighton Collaboration: creating a global standard for case definitions (and guidelines) for adverse events following immunization. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 February.
14. Yameogo T.M., Breugelmans J.G., Kambou J.L., Badolo O., Tiendrebéogo S., Traoré E., et al. Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations. Med Trop (Mars) 2009, 69(August (4)):320-321.
15. Bentsi-Enchill A.D., Zongo I., Khamassi S., Pless R., Thombiano R., Tiéndrebéogo S., et al. Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso. Vaccine 2007, 25(3 September (Suppl 1)):A72-A78.
16. Bonhoeffer J., Bentsi-Enchill A., Chen R.T., Fisher M.C., Gold M.S., Hartman K., et al. Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine 2009, 27(6 April (16)):2282-2288.
17. Bonhoeffer J., Bentsi-Enchill A., Chen R.T., Fisher M.C., Gold M.S., Hartman K., et al. Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine 2009, 27(6 April (16)):2289-2297.
18. Hughes M.L., Whittlesea C.M., Luscombe D.K. Review of national spontaneous reporting schemes. Strengths and weaknesses. Adverse Drug React Toxicol Rev 2002, 21(4):231-241.
19. Fitzner J., Coulibaly D., Kouadio D.E., Yavo J.C., Loukou Y.G., Koudou P.O., et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan Ivory Coast. Vaccine 2004, 23(25 November (2)):156-162.
20. World Health Organization Causality assessment of adverse events following immunization. Wkly Epidemiol Rec 2001, 76(23 March (12)):85-89.
21. World Health Organization. Training on monitoring and management of adverse events following immunization. 5-9-2005. 17-5-2012. Ref Type: Online Source.
22. EpiInfo 2000 [computer program]; 2004.
23. Pollabauer E.M., Petermann R., Ehrlich H.J. Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology. Hum Vaccin 2005, 1(July (4)):131-139.
24. Page A.L., Hustache S., Luquero F.J., Djibo A., Manzo M.L., Grais R.F. Health care seeking behavior for diarrhea in children under 5 in rural Niger: results of a cross-sectional survey. BMC Public Health 2011, 11:389.
25. Centers for Disease Control and Prevention Nutritional and health status of children during a food crisis-Niger, September 17-October 14, 2005. MMWR Morb Mortal Wkly Rep 2006, 55(3 November (43)):1172-1176.
26. Nandy R., Handzel T., Zaneidou M., Biey J., Coddy R.Z., Perry R., et al. Case-fatality rate during a measles outbreak in eastern Niger in 2003. Clin Infect Dis 2006, 42(1 February (3)):322-328.
27. Andrews N., Stowe J., Miller E., Taylor B. Post-licensure safety of the meningococcal group C conjugate vaccine. Hum Vaccin 2007, 3(March (2)):59-63.
28. Rougemont A., Breslow N., Brenner E., Moret A.L., Dumbo O., Dolo A., et al. Epidemiological basis for clinical diagnosis of childhood malaria in endemic zone in West Africa. Lancet 1991, 338(23 November (8778)):1292-1295.
29. World Health Organization Meeting of the Global Advisory Committee on Vaccine Safety June 2011. Wkly Epidemiol Rec 2011, 86(22 July (30)):321-324.
30. Mark A., Carlsson R.M., Granstrom M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 1999, 17(9 April (15-16)):2067-2072.
31. Hersh B.S., Carr R.M., Fitzner J., Goodman T.S., Mayers G.F., Everts H., et al. Ensuring injection safety during measles immunization campaigns: more than auto-disable syringes and safety boxes. J Infect Dis 2003, 187(15 May (Suppl 1)):S299-S306.
32. Pless R.P., Bentsi-Enchill A.D., Duclos P. Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues. J Infect Dis 2003, 187(15 May (Suppl 1)):S291-S298.
33. Lancet Infectious Diseases A vaccine against meningitis in Africa. Lancet Infect Dis 2011, 11(January (1)):1.
34. Iskander J.K., Chen R.T. Vaccine preventable diseases. Part 2: Public health surveillance for vaccine adverse events. Infectious disease surveillance 2007, 241-253. Blackwell Publishing. N.M. M'ikanatha, R. Lynfield, C.A. Van Benenden, H. de Valk (Eds.).
35. Rosenthal S., Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995, 85(December (12)):1706-1709.
36. McClure D.L., Glanz J.M., Xu S., Hambidge S.J., Mullooly J.P., Baggs J. Comparison of epidemiologic methods for active surveillance of vaccine safety. Vaccine 2008, 26(19 June (26)):3341-3345.
37. Edwards I.R., Lindquist M. First, catch your signal!. Drug Saf 2010, 33(1 April (4)):257-260.
38. Andrews N.J. Statistical assessment of the association between vaccination and rare adverse events post-licensure. Vaccine 2001, 20(15 October (Suppl 1)):S49-S53.
39. Kramarz P., France E.K., Destefano F., Black S.B., Shinefield H., Ward J.I., et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 2001, 20(April (4)):410-416.
40. Lindquist M., Edwards I.R. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol 2001, 28(May (5)):1180-1187.
41. Duclos P., Delo A., Aguado T., Bilous J., Birmingham M., Kieny M.P., et al. Immunization safety priority project at the World Health Organization. Semin Pediatr Infect Dis 2003, 14(July (3)):233-239.
42. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration-enhancing vaccine safety. Vaccine 2004, 22(7 May (15-16)):2046.